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Prosthesis-annular length and QRS duration before and immediately after
TAVI implantation were compared to the need of permanent pacing.
Results: The TAVI procedure was successfully performed in all and per-
manent pace maker implantation was required in 7 patients (20%) because of
a complete AV block occurring during the 3 days after TAVI procedure.
Patients requiring a permanent pacing had greater prosthesis-annular length
(11±4 mm vs. 8±4 mm, p=0.03) and QRS duration after implantation
(137±24 ms vs. 161±3 ms, p=0.006), while no difference was observed for
baseline QRS duration. QRS enlargement correlated with prosthesis annular
length (r=0.4, p=0.01). Interestingly, all patients with QRS enlargement
<48 ms (n=20) were free of complete AV block, while permanent pacing was
required in 54% (7/15) of patients with a QRS enlargement >48 ms (n=15).
Conclusions: In patients with a limited changes in QRS duration (<48 ms)
after TAVI procedure, the risk of complete block seems limited, while QRS
enlargement >48ms appears strongly associated to the need of permanent pacing.
197
Percutaneous mitral commisurotomy in patients aged 50 years and more
Zied Frikha [Orateur] (1), Salma Longo (2), Mahdi Ben Sassi (3), Baha Alhabil
(3), Ihsen Zairi (4), Sofien Kammoun (5), Sana Fennira (4), Sondos Kraim (6)
(1) Cardiologie, Sfax, Tunisie  (2) Hôpital Habib Thameur, Cardiologie,
Tunis, Tunisie  (3) Hôpital Habib Thameur, Cardiologie, Tunis, Tunisie (4)
Hôpital Habib Thameur, Cardiologie, Tunis, Tunisie  (5) Hôpital Habib Tha-
meur, Cardiologie, Tunis, Tunisie  (6) Hôpital Habib Thameur , Cardiologie,
Tunis, Tunisie
Introduction: The studies concerning the percutaneous mitral commis-
surotomy (PMC) in the elderly patients are rare.
Objectives: The purpose of this work is the study of early ,mid and long-
term results of the PMC in patients aged more than 50-years and their com-
parison with the results obtained in the younger patients.
Materials and methods: retrospective study of 170 patients, hospitalized
in the cardiology department between January 1994 and January 2008 having
PMC by balloon inoué with a clinical and echocardiographic follow-up of
more than 10 years. We defined the patients >=50 years old (group1) and the
patients aged less than 50-years (group 2)
Results: – 45 patients were >= 50 years old (17,05%). The mean age was
56,41%. 62,1% were in atrial fibrillation (AF) and 37,9% were in sinus
rhythm(SR) . The WILKINS score showed that 20,7% had a score <8,72, 4%
between 9-11 and 6,9% a score >12. After PMC the mean mitral area was
passed from 1,07+–0,2 cm2 to 2,03+–0,3 cm2 (p<0,001), the transmitral gra-
dient was passed from 14,88+–5,14 mmhg to 3,99+–2,26 (p<0,001) and the
mean pulmonary artery pressure was passed from 35,66 +–9,97 mmhg to
24,34 +–9,48 mmhg (p<0,01). The estimation of Kaplan-Meier showed that
the absence of restenosis was respectively 80,8%;73,1%; 65,4% and 61,5% in
3,5,7 and 10 years. – the Comparison between both groups of the young and
the elderly patients showed that in the (group 2) the majority of patients were
in SR (91,7%) however in the (group) the majority were in AF (61,7%). In our
study, in the (group 2) there were no patients having a high score of
WILKINS >11, however in the (group 1) 6,9% had a score of WILKINS >11.
Finaly in the (group 2) the percentage of patients having had a restenosis is
14,3%; however in the (group1) restenosis was noted in 38,46%.
Conclusion: PMC is effective first therapy in patients aged >=50 years
with symptomatic mitral stenosis.
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Objective: To assess the impact of coronary artery disease management on
prognosis in patients undergoing transcatheter aortic valve implantation (TAVI).
Methods: 121 patients (53 men, 85±7 years) with severe symptomatic aortic
stenosis (Aortic Valve Area [AVA]=0.7±0.2 cm², gradient=43±15 mmHg,
LVEF=47±13%, logistic Euroscore 27±13%) underwent TAVI using
Medtronic Corevalve® bioprosthesis. Coronary angiography was performed in
all before the procedure. Significant coronary lesions (50%) were treated by
angioplasty one month before the procedure or medically treated (aspirin,
statin and betablocker). Revascularization strategy was left free to the clinician
appreciation and compared to primary outcome (heart failure, myocardial inf-
arction and mortality).
Results: Of the 121 patients, 57% exhibited significant coronary artery
stenosis (45% monotroncular, 35% bitroncular and 20% tritroncular) with
proximal coronary stenosis 70% in 73%. Revascularization was per-
formed in 23 patients (78% with proximal stenosis 70%) and medical
treatment in 38 patients (45% with proximal stenosis 70%). TAVI proce-
dure was successfully performed in all patients with AVA and mean
LVOT gradient after implantation averaging 2.0±0.4 cm² and 9±4 mmHg,
respectively. Mean follow-up duration was 194±23 days. Primary outcome
[heart failure (n=10), myocardial infarction (n=1) and mortality (n=27)]
was similarly observed in the coronary angioplasty and medical treatment
groups (26% vs. 32%; p=0.81). Interestingly, poor outcome was only asso-
ciated to procedure duration (94±6 min vs. 72±6 min, p=0.015) and greater
peak troponin I after procedure (0.98±0.2 vs. 0.24±0.1, p=0.0001). Fur-
thermore, increase in troponin I after TAVI was observed in all patients
after the procedure independently to the presence of significant coronary
stenosis or to revascularization strategy.
Conclusion: Coronary artery revascularization before TAVI does not
impact clearly on outcome. The association between peak troponin after pro-
cedure and prognosis suggests that an alternative strategy to better protect
myocardial function should be investigated.
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Background: Transcatheter aortic valve implantation (TAVI) is a growing
cardiac intervention using ionising radiation with deterministic and stochastic
effects for the patient as well as for the medical heart team. Dose area product
(DAP) evaluates radiation dose and is easily found on the X-ray tube program
at the end of the procedure. We aimed to measure the dose of radiation
emitted during TAVI, and to compare with coronary angiogram (CA) or per-
cutaneous coronary interventions (PCI).
Methods: We perform TAVI, CA and PCI in the same cath lab. We com-
pare DAP as noted at the end of each procedure for these 3 types of interven-
tion over the same period (September 2008 to June 2010). For TAVI, we also
analysed the role of technical (femoral vs apical approach) and patient-related
features (weight, body surface area).
Results: During the study period, we consecutively included 37 cases
of TAVI, 1230 CA, 89 isolated PCI and 807 CA with ad hoc PCI. DAP
was significantly higher in TAVI than in CA alone (83.3 vs 44.9 Gy.cm²,
p<0.01), but no significant difference was observed between TAVI and
PCI and CA/PCI (respectively 70.1 and 90 Gy.cm²). Among TAVI, there
was a significant difference between transapical approach and transfemoral
approach (80 vs 86.3 Gy.cm² respectively, p=0.05). DAP was also influ-
enced by patient’s weight (p <0.01, r²=0.29) and body surface area
(p<0.01, r²=0.32).
Conclusion: The radiation dose related to TAVI is twice that of coronary
angiogram, and similar to that of coronary angiogram with ad hoc PCI.
